Vericel Corporation VCEL

VCEL Company Overview

Vericel Corporation is a U.S.-based regenerative medicine company focused on the development, manufacture, and commercialization of advanced cell therapies for the treatment of severe musculoskeletal and burn injuries. The company operates within the biotechnology and regenerative medicine industries, with a commercial emphasis on autologous cell-based therapies that address high unmet medical needs. Vericel’s revenue is primarily driven by two FDA-approved products targeting orthopedic cartilage repair and severe burn care.

The company’s core products are MACI (Matrix-Induced Autologous Chondrocyte Implantation), used for the repair of symptomatic cartilage defects of the knee, and Epicel, a cultured epidermal autograft for patients with deep dermal or full-thickness burns. Vericel primarily serves orthopedic surgeons, burn centers, and specialized hospitals in the United States, positioning itself as a niche leader in cell-based regenerative therapies with limited direct competition due to regulatory complexity and manufacturing barriers.

Vericel was formed in 2014 following the acquisition of certain cell therapy assets from Genzyme Corporation by Aastrom Biosciences. The company subsequently rebranded as Vericel Corporation in 2015 and shifted its strategic focus from early-stage cell therapy research to commercial-stage regenerative medicine products. This evolution marked a transition toward disciplined execution, manufacturing scale, and commercialization of FDA-approved therapies.